Phase 2b, Proof-of-Concept, Single-center, Double-Masked, Randomized Study Comparing the Safety, Tolerability, and Efficacy of Three Different Ophthalmic Eyelid Wipe Dosing Techniques Using IVW-1001 in Subjects With Dry Eye Disease
Latest Information Update: 01 Apr 2026
At a glance
- Drugs IVIEW 1001 (Primary)
- Indications Dry eyes
- Focus Proof of concept; Therapeutic Use
- Sponsors iView Therapeutics
Most Recent Events
- 27 Mar 2026 Status changed from active, no longer recruiting to completed.
- 15 Jan 2026 According to an IVIEW Therapeutics media release, the data from the trial will be presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, to be held in Denver, Colorado on May 3-7, 2026.
- 23 Sep 2025 Status changed from not yet recruiting to active, no longer recruiting.